SEC Tracker
Get the app

Plus Therapeutics CNSY

Cerenome reported a net loss of $4.42 million

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $1.4 million for the three months ended Sep 30, 2025
  2. Net loss: $4.42 million for the three months ended Sep 30, 2025
  3. Cash and equivalents: $13.29 million at Sep 30, 2025

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Plus Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 3 claims matched the filing text.

Not found in the filing text

  • The company reported revenue of $411,000 for the quarter.
  • The operating margin was -2203.6%.
  • The net margin was -2191.2%.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. QT Imaging Holdings QTI public float $33M, Jun 30, 2025
  2. NutriBand NTRB
  3. Femasys FEMY public float $30M, Jun 30, 2025
  4. DarioHealth DRIO public float $28M, Jun 30, 2025
  5. HeartBeam BEAT public float $36M, Jun 30, 2025